Research programme: mRNA COVID-2019 vaccines - Sorrento Therapeutics
Latest Information Update: 28 Sep 2025
At a glance
- Originator Sorrento Therapeutics
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Intralymphatic)
- 20 Mar 2022 Sorrento Therapeutics intends to seek Emergency Use Authorisation (EUA) approval in Mexico
- 20 Mar 2022 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by Sorrento Therapeutics